Free tool
FAERS Monitor: Monjuvi
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming BLA 761163 or its brand name (Monjuvi, Tafasitamab-Cxix). Reports on generic versions are filed under their own applications.
Reports
906
Serious
665
73% of reports
Hospitalization
144
Death reported
131
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- disease progression239
- off label use168
- lymphoma165
- death66
- drug ineffective47
- diffuse large b-cell lymphoma42
- neutropenia39
- blood lactate dehydrogenase increased38
- malignant neoplasm progression38
- covid-1930
- polyneuropathy29
- diarrhoea28
- pyrexia28
- product use issue27
- cytopenia26
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 12 |
| 2021 | 93 |
| 2022 | 179 |
| 2023 | 380 |
| 2024 | 135 |
| 2025 | 65 |
| 2026 | 42 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,253 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| lymphomaSignal | 165 | 250.6 | 218.1 | 40,371 |
| diffuse large b-cell lymphomaSignal | 42 | 127.2 | 94.6 | 5,108 |
| polyneuropathySignal | 29 | 56.4 | 39.4 | 1,520 |
| blood lactate dehydrogenase increasedSignal | 38 | 55.8 | 40.8 | 1,987 |
| cytopeniaSignal | 26 | 49.4 | 33.8 | 1,183 |
| disease progressionSignal | 239 | 47.0 | 42.1 | 10,749 |
| malignant neoplasm progressionSignal | 38 | 8.6 | 6.3 | 249 |
| neutropeniaSignal | 39 | 6.7 | 4.9 | 183 |
| off label useSignal | 168 | 4.5 | 3.9 | 466 |
| covid-19Signal | 30 | 4.0 | 2.8 | 64 |
| product use issueSignal | 27 | 3.3 | 2.3 | 42 |
| pyrexia | 28 | 1.9 | 1.3 | 11 |
| death | 66 | 1.8 | 1.4 | 23 |
| diarrhoea | 28 | 1.0 | 0.7 | 0 |
| drug ineffective | 47 | 0.8 | 0.6 | 2 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.